Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
Avidicure, a biotechnology company pioneering a completely new multifunctional antibody modality with broad potential in oncology, announced its launch following a $50 million seed financing round. The round was led by EQT Life Sciences, with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures.
Avidicure is developing dual agonistic, multifunctional and avidity engineered antibodies, “AVC-Boosters”, that can safely deliver targeted and potent cancer monotherapy. AVC-Boosters unlock strong and orchestrated immunological responses, harnessing the full power of both the innate and adaptive immune system. The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers, and antibody-drug conjugates (ADCs).
“AVC-Boosters have the potential to change the treatment landscape for a wide range of cancers as first-in-class multifunctional antibody products that safely mobilize the full power of the immune system,” said Arthur Lahr, Chief Executive Officer of Avidicure. “Our products drive targeted and potent immune responses only in the tumor with reduced toxicity risk. We are eager to build a broad pipeline with our unique platform and progress our lead oncology product, AVC-S-101, into clinical development for solid tumors.”
Read more here.
Find more news here.